Shares of Novacyt S.A. (LON:NCYT – Get Free Report) traded down 1.6% during trading on Wednesday. The stock traded as low as GBX 35.80 and last traded at GBX 35.80. 5,756 shares changed hands during trading, a decline of 96% from the average session volume of 160,385 shares. The stock had previously closed at GBX 36.40.
Novacyt Stock Down 1.6%
The firm has a market capitalization of £25.96 million, a PE ratio of -1.15 and a beta of 1.11. The business’s 50 day simple moving average is GBX 39.37 and its 200 day simple moving average is GBX 38.31. The company has a current ratio of 3.14, a quick ratio of 4.46 and a debt-to-equity ratio of 54.74.
Novacyt (LON:NCYT – Get Free Report) last posted its earnings results on Wednesday, September 30th. The company reported GBX (8) earnings per share for the quarter. Novacyt had a negative return on equity of 159.13% and a negative net margin of 102.66%.
About Novacyt
Novacyt is an international molecular diagnostics company providing a broad portfolio of integrated technologies and services, primarily focused on the delivery of genomic medicine. The Company develops, manufactures, and commercialises a range of molecular assays and instrumentation to deliver workflows and services that enable seamless end-to-end solutions from sample to result across multiple sectors including human health, animal health and environmental. The Company is divided into three business segments: Clinical Broad portfolio of human clinical in vitro diagnostic products, workflows and services focused on three therapeutic areas: · Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy tests · Precision Medicine: DPYD genotyping assay · Infectious Diseases: Winterplex, multiplex winter respiratory PCR panel Instrumentation Portfolio of next generation size selection DNA sample preparation platforms and rapid PCR machines, including: · Ranger® Technology: automated DNA sample preparation and target enrichment technology MyGo: real-time quantitative PCR (qPCR) instruments Research Use Only Range of services for the life sciences industry: · Design, manufacture, and supply of high-performance qPCR assays and workflows for use in human health, agriculture, veterinary and environmental, to support global health organisations and the research industry · Pharmaceutical research services: whole genome sequencing (WGS) / whole exome sequencing (WES) Novacyt is headquartered in Vélizy-Villacoublay in France with offices in the UK (in Stokesley, Eastleigh and Manchester), Taipei, Singapore, the US and Canada and has a commercial presence in over 65 countries.
See Also
- Five stocks we like better than Novacyt
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Novacyt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novacyt and related companies with MarketBeat.com's FREE daily email newsletter.
